dc.contributor.author | Donners, R | |
dc.contributor.author | Fotiadis, N | |
dc.contributor.author | Figueiredo, I | |
dc.contributor.author | Blackledge, M | |
dc.contributor.author | Westaby, D | |
dc.contributor.author | Guo, C | |
dc.contributor.author | Fenor de la Maza, MDLD | |
dc.contributor.author | Koh, D-M | |
dc.contributor.author | Tunariu, N | |
dc.coverage.spatial | Germany | |
dc.date.accessioned | 2022-09-27T11:06:21Z | |
dc.date.available | 2022-09-27T11:06:21Z | |
dc.date.issued | 2022-07-26 | |
dc.identifier | 10.1007/s00330-022-09011-y | |
dc.identifier.citation | European Radiology, 2022, 32 (10), pp. 6820 - 6829 | |
dc.identifier.issn | 0938-7994 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5504 | |
dc.identifier.eissn | 1432-1084 | |
dc.identifier.eissn | 1432-1084 | |
dc.identifier.doi | 10.1007/s00330-022-09011-y | |
dc.description.abstract | OBJECTIVES: Investigate the laboratory, imaging and procedural factors that are associated with a tumour-positive and/or NGS-feasible CT-guided sclerotic bone lesion biopsy result in cancer patients. METHODS: In total, 113 CT-guided bone biopsies performed in cancer patients by an interventional radiologist in one institution were retrospectively reviewed. Sixty-five sclerotic bone biopsies were eventually included and routine blood parameters and tumour marker levels were recorded. Non-contrast (NC) biopsy CTs (65), contrast-enhanced CTs (24), and PET/CTs (22) performed within four weeks of biopsy were reviewed; lesion location, diameter, lesion-to-cortex distance, and NC-CT appearance (dense-sclerosis versus mild-sclerosis) were noted. Mean NC-CT, CE-CT HU, and PET SUVmax were derived from biopsy tract and lesion segmentations. Needle diameter, tract length, and number of samples were noted. Comparisons between tumour-positive/negative and next-generation sequencing (NGS)-feasible/non-feasible biopsies determined significant (p < 0.05) laboratory, imaging, and procedural parameter differences. RESULTS: Seventy-four percent of biopsies were tumour-positive. NGS was feasible in 22/30 prostate cancer patients (73%). Neither laboratory blood parameters, PET/CT availability, size, nor lesion-to-cortex distance affected diagnostic yield or NGS feasibility (p > 0.298). Eighty-seven percent of mildly sclerotic bone (mean 244 HU) biopsies were positive compared with 56% in dense sclerosis (622 HU, p = 0.005) and NC-CT lesion HU was significantly lower in positive biopsies (p = 0.003). A 610 HU threshold yielded 89% PPV for tumour-positive biopsies and a 370 HU threshold 94% PPV for NGS-feasible biopsies. FDG-PET and procedural parameters were non-significant factors (each p > 0.055). CONCLUSION: In cancer patients with sclerotic bone disease, targeting areas of predominantly mild sclerosis in lower CT-attenuation lesions can improve tumour tissue yield and NGS feasibility. KEY POINTS: • Areas of predominantly mild sclerosis should be preferred to areas of predominantly dense sclerosis for CT-guided bone biopsies in cancer patients. • Among sclerotic bone lesions in prostate cancer patients, lesions with a mean HU below 370 should be preferred as biopsy targets to improve NGS feasibility. • Laboratory parameters and procedure related factors may have little implications for CT-guided sclerotic bone biopsy success. | |
dc.format | Print-Electronic | |
dc.format.extent | 6820 - 6829 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | European Radiology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Bone marrow | |
dc.subject | Computer tomography | |
dc.subject | Genomics | |
dc.subject | Image-guided biopsy | |
dc.subject | Neoplasms | |
dc.subject | Bone Diseases | |
dc.subject | Bone Neoplasms | |
dc.subject | Cartilage Diseases | |
dc.subject | Humans | |
dc.subject | Image-Guided Biopsy | |
dc.subject | Male | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Retrospective Studies | |
dc.subject | Sclerosis | |
dc.subject | Tomography, X-Ray Computed | |
dc.title | Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-06-30 | |
dc.date.updated | 2022-09-27T11:05:49Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1007/s00330-022-09011-y | |
rioxxterms.licenseref.startdate | 2022-07-26 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35881184 | |
pubs.issue | 10 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Computational Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/20/21 Starting Cohort | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1007/s00330-022-09011-y | |
pubs.volume | 32 | |
icr.researchteam | Computational Imaging | |
icr.researchteam | Translational Therapeutic | |
dc.contributor.icrauthor | Blackledge, Matthew | |
dc.contributor.icrauthor | Westaby, Daniel | |
dc.contributor.icrauthor | Guo, Wei Yu | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof Chris Lord) on 2022-09-27. Deposit type is initial. No. of files: 1. Files: Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.pdf | |